

Cancer Stem Cells: Getting Past the Controversies – Academic and Industry Perspectives on Key Targets & Development Paths

Jeremy P. Goldberg
JPG Healthcare LLC

24th Annual Cancer Progress Conference
March 5th – 6th, 2013

The logo for Cancer Progress by Defined Health. It features the word "CANCER" in a large, black, sans-serif font. Below it, the word "PROGRESS" is written in a much larger, bold, black, sans-serif font. Underneath "PROGRESS" is the tagline "by Defined Health" in a smaller, italicized, black, sans-serif font. The entire text is overlaid on a large, light blue, tilted oval shape.

CANCER
PROGRESS
by Defined Health

Cancer Stem Cells: Getting Past the Controversies – Academic and Industry Perspectives on Key Targets & Development Paths

Moderator:

- Jeremy P. Goldberg, President, JPG Healthcare LLC

Panelists:

- George Q. Daley, MD, PhD, Samuel E. Lux IV Professor of Hematology-Oncology and Director, Stem Cell Transplantation, Program, Children's Hospital/ Dana Farber Cancer Institute; Professor of Biological Chemistry , Harvard Medical School; Investigator, Howard Hughes Medical Institute
- Jonathan Pachter, PhD, Vice President & Head, Research, Verastem, Inc.
- Kenichi Nomoto, PhD, President of Eisai Oncology Unit
- Eric Rowinsky, MD, Chief Medical Officer, Head of Research & Development, Stemline Therapeutics, Inc.




Cancer Stem Cells: Fast Growing Interest in the Space Using Surrogate of PubMed Articles

Nat Med. 1997 Jul;3(7):730-7.

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell.

Bonnet D, Dick JE.



Companies Range from Committed CSC-Focused Companies to Those With a Single CSC-Relevant Product



Selected Cancer Stem Cell Deals

Originator	Partner	Product/Program/Platform	Deal Terms	Date
Verastem	Eisai	Next gen small molecule wnt inhibitors	VS-507 is a proprietary formulation of salinomycin and will be the starting point for the development of proprietary analogs	July 2012
Boston Biomedical	Dainippon	Undisclosed CSC targets BBI608 Phase III BBI503 Phase I	\$2.6B \$200 million down, \$540 million in development milestones for its two clinical-stage programs and close to \$1.9 billion in commercial milestones	Feb 2012
QuanticeL	Celgene	Single cell genomic analysis with focus on pathways relevant to CSCs	\$45M plus equity stake	Nov 2011
PRISM BioLab	Eisai	Inhibitors of the CBP/ β -catenin	Exclusive worldwide rights (excluding some countries) for the development and commercialization	April 2011
OncoMed	Bayer	Anti-Wnt antibodies and SMIs	\$40 million upfront, option to buy up to five programs through Phase I, up to \$387.5 million for each new biologic and \$112 million for each small molecule drug that gets approved	June 2010

Cancer Stem Cells: Getting Past the Controversies – Academic and Industry Perspectives on Key Targets & Development Paths

Moderator:

- Jeremy P. Goldberg, President, JPG Healthcare LLC

Panelists:

- George Q. Daley, MD, PhD, Samuel E. Lux IV Professor of Hematology-Oncology and Director, Stem Cell Transplantation, Program, Children's Hospital/ Dana Farber Cancer Institute; Professor of Biological Chemistry , Harvard Medical School; Investigator, Howard Hughes Medical Institute
- Jonathan Pachter, PhD, Vice President & Head, Research, Verastem, Inc.
- Kenichi Nomoto, PhD, President of Eisai Oncology Unit
- Eric Rowinsky, MD, Chief Medical Officer, Head of Research & Development, Stemline Therapeutics, Inc.

